Publications by authors named "Mai Ueno"

Toxoplasma gondii (T. gondii) is a zoonotic protozoan parasite that causes congenital toxoplasmosis, including fetal death, abortion, stillbirth, morphological abnormalities, and premature birth. Primary T.

View Article and Find Full Text PDF
Article Synopsis
  • Roxadustat is an approved medication in China for treating anemia in patients with dialysis-dependent chronic kidney disease (CKD), focusing on Japanese hemodialysis patients who were either new to treatment or had switched from erythropoiesis-stimulating agents (ESAs).
  • In two open-label studies, patients were given varying doses of oral roxadustat over 24 to 52 weeks, where average hemoglobin levels reached around 10.93 g/dL, and a maintenance rate of hemoglobin levels between 10.0-12.0 g/dL was achieved in over 70% of participants.
  • The most common treatment-emergent adverse event was nasopharyngitis, with two deaths
View Article and Find Full Text PDF

Multiple imputation is a promising approach for handling of missing data. One uncertainty in applications of the multiple imputation to randomized controlled trials with longitudinal data is whether the imputation should be carried out across all subjects simultaneously or by treatment group separately, which leads to two different strategies for building imputation procedures and/or models. Indeed, it has not been sufficiently addressed and well-documented how the two imputation strategies work in the analysis of the longitudinal data.

View Article and Find Full Text PDF

Roxadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor developed to treat anemia in chronic kidney disease (CKD) patients. This Phase 3, randomized, open-label, 24-week study investigated the efficacy and safety of roxadustat in Japanese CKD patients with anemia on peritoneal dialysis (PD) who were previously treated or not treated with erythropoiesis stimulating agents (ESAs). Patients not previously receiving ESA (ESA-Naïve group) were randomized to roxadustat at a starting dose of 50 or 70 mg three times weekly; patients previously receiving ESA (ESA-Converted group) switched from ESA to roxadustat 70 or 100 mg three times weekly depending on the prior ESA dose.

View Article and Find Full Text PDF

Roxadustat is a hypoxia-inducible factor prolyl hydroxylase inhibitor in late-stage clinical development for the treatment of anemia in chronic kidney disease. Spherical carbon adsorbent (SCA) is used in patients with chronic kidney disease and has been shown to impact absorption of certain concomitant drugs. Two phase 1, open-label, randomized, crossover studies were conducted in healthy adult Japanese males to investigate the effect of food and SCA on the pharmacokinetics of a single oral dose of roxadustat.

View Article and Find Full Text PDF

[Purpose] Rhythmic auditory stimulation has been used in gait training for stroke patients. However, few studies have investigated its effects in relation to lesion sites. Therefore, this study examined the immediate effects of rhythmic auditory stimulation on gait in stroke patients with lesions in different regions.

View Article and Find Full Text PDF

We investigated the effects of sodium alginate oligosaccharides (alginate) on the development of spontaneous hypertension in rats. Spontaneous hypertensive rats were treated with alginate for 7 weeks. Systolic blood pressure (SBP) and cardiovascular and kidney damage were assessed.

View Article and Find Full Text PDF

Objective: We investigated the effects of long-term miso soup drinking on salt-induced hypertension in Dahl salt-sensitive (Dahl S) rats.

Methods: Dahl S rats were divided into four groups that consumed 1) water, 2) a 0.9% NaCl solution, 3) a 1.

View Article and Find Full Text PDF

Objectives: In this article, the antihypertensive effects of sodium alginate oligosaccharides, enzymatic products of high molecular natural alginate from sea weeds, in Dahl salt-sensitive (Dahl S) rats were investigated.

Material And Methods: Dahl S rats fed a high-salt (4% NaCl) diet were treated with sodium alginate oligosaccharides (4% or 8% w/w) for 7 weeks. Systolic blood pressure (SBP) was measured by the tail-cuff method, and hypertensive cardiovascular benefits and kidney damage were assessed.

View Article and Find Full Text PDF